Wing C Chan

US Patent:

7431022, Oct 7, 2008

Filed:

Jul 24, 2007

Appl. No.:

11/880781

Inventors:

Zhouxuan Xia - Windsor, CA
Kevin Mulkeran - Holly MI, US
Wing Chan - Novi MI, US
Hans Jensen - West Bloomfield MI, US

Assignee:

Mahle Technology, Inc. - Farmington Hills MI

International Classification:

F02M 37/04

US Classification:

123520, 123198 D

Abstract:

An evaporative emission canister purge actuation monitoring system includes an integrated valve body having a main flow passage, a first one-way umbrella valve mounted to the valve body that is responsive to predetermined positive pressure in the main flow passage to control flow of fluid from a vapor canister to ambient air as well as a second one-way umbrella valve that is responsive to a predetermined negative pressure in the main flow passage to control the flow of ambient air through a fresh air port. A vacuum actuated switch is supported by the integrated valve body and in electrical communication with a control unit. The switch is responsive to negative pressure in the main flow passage to send a signal indicative of the predetermined negative pressure to the control unit.

US Patent:

8131475, Mar 6, 2012

Filed:

Jul 25, 2006

Appl. No.:

11/493387

Inventors:

Louis M. Staudt - Silver Spring MD, US
George Wright - Rockville MD, US
Sandeep Dave - Washington DC, US
Bruce Tan - Baltimore MD, US
John I. Powell - Ijamsville MD, US
Wyndham Wilson - Washington DC, US
Elaine Jaffe - Great Falls VA, US
Wing C. Chan - Omaha NE, US
Timothy C. Greiner - Council Bluffs IA, US
Dennis Weisenburger - Elkhom NE, US
James Armitage - Omaha NE, US
Kai Fu - Omaha NE, US
Richard I. Fisher - Pittsford NY, US
Lisa Rimsza - Tucson AZ, US
Thomas Miller - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Elias Campo - Barcelona, ES
Silvia M Bea - Sabadell, ES
Itziar Salaverria - Barcelona, ES
Armando Lopez-Guillermo - Barcelona, ES
Emili Montserrat - Barcelona, ES
Victor Moreno - Barcelona, ES
Andreas Zettl - Würzburg, DE
German Ott - Würzburg, DE
Hans-Konrad Muller-Hermelink - Wuerzburg, DE
Andreas Rosenwald - Wuerzburg, DE
Julie Vose - Omaha NE, US
Randy Gascoyne - North Vancouver, CA
Joseph Connors - Vancouver, CA
Erlend Smeland - Oslo, NO
Stein Kvaløy - Oslo, NO
Harald Holte - Oslo, NO
Jan Delabie - Oslo, NO
T. Andrew Lister - London, GB

Assignee:

The United States of America as represented by the Secretary, Department of Health and Human Services - Washington DC
Board of Regents of the University of Nebraska - Lincoln NE
University of Rochester - Rochester NY
Arizona Board of Regents of Behalf of the University of Arizona - Tucson AZ
Universitat de Barcelona - Barcelona
Fundacio Clinic - Barcelona
Hospital Clinic - Barcelona
Julius-Maximilians-University of Wuerzburg - Wuerzburg
British Columbia Cancer Agency Branch - Vancouver
Oslo University Hospital HF - Oslo
Queen Mary and Westfield College, University of London - London

International Classification:

G01N 33/48
C12Q 1/68
G06G 7/58

US Classification:

702 19, 435 6, 702 20, 703 11

Abstract:

Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

US Patent:

20090084362, Apr 2, 2009

Filed:

Sep 28, 2007

Appl. No.:

11/863981

Inventors:

Wing Chan - Novi MI, US
Kevin Mulkeran - Holly MI, US

International Classification:

F02M 33/02

US Classification:

123519

Abstract:

Compositions for use in evaporative emission control systems are disclosed and described. The compositions include a fuel adsorbent material mixed with a catalyst. The catalyst is polymeric and has a specific heat that is higher than the specific heat of the fuel adsorbent material.

US Patent:

20090132147, May 21, 2009

Filed:

Nov 19, 2007

Appl. No.:

11/986278

Inventors:

Hans Jensen - West Bloomfield MI, US
Zhouxuan Xia - Windsor, CA
Kevin Mulkeran - Holly MI, US
Wing Chan - Novi MI, US

International Classification:

F02D 45/00
F02M 33/02
B01D 35/02

US Classification:

701102, 123520, 96108

Abstract:

An evaporative emission canister purge actuation monitoring system includes an integrated valve body having a main flow passage, and an air filter assembly disposed adjacent the valve body and providing fluid communication between the main flow passage and the ambient air. A first one-way umbrella valve mounted to the valve body that is responsive to predetermined positive pressure in the main flow passage to control flow of fluid from a vapor canister to ambient air as well as a second one-way umbrella valve that is responsive to a predetermined negative pressure in the main flow passage to control the flow of ambient air through a fresh air port.

US Patent:

20120225793, Sep 6, 2012

Filed:

Mar 1, 2012

Appl. No.:

13/409416

Inventors:

Louis M. Staudt - Silver Spring MD, US
George Wright - Rockville MD, US
Sandeep Dave - Washington DC, US
Bruce Tan - Baltimore MD, US
John I. Powell - Ijamsville MD, US
Wyndham Wilson - Washington DC, US
Elaine Jaffe - Great Falls VA, US
Wing C. Chan - Omaha NE, US
Timothy C. Greiner - Council Bluffs IA, US
Dennis Weisenburger - Elkhorn NE, US
James Armitage - Omaha NE, US
Kai Fu - Omaha NE, US
Richard I. Fisher - Pittsford NY, US
Lisa Rimsza - Tucson AZ, US
Thomas Miller - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Elias Campo - Barcelona, ES
Silvia M. Bea - Sabadell, ES
Itziar Salaverria - Barcelona, ES
Armando Lopez-Guillermo - Barcelona, ES
Emili Montserrat - Barcelona, ES
Victor Moreno - Barcelona, ES
Andreas Zetti - Wurzburg, DE
German Ott - Wurzburg, DE
Hans-Konrad Muller-Hermelink - Wuerzburg, DE
Andreas Rosenwald - Wuerzburg, DE
Julie Vose - Omaha NE, US
Randy Gascoyne - North Vancouver, CA
Joseph Connors - Vancouver, CA
Erlend Smeland - Oslo, NO
Stein Kvaloy - Oslo, NO
Harald Holte - Oslo, NO
Jan Delabie - Oslo, NO
T. Andrew Lister - London, GB

Assignee:

The United States of America, as Represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
Board of Regents of the University of Nebraska - Lincoln NE
University of Rochester - Rochester NY
Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ
Universitat De Barcelona - Barcelona
Queen Mary and Westfield College, University of London - London
Hospital Clinic - Barcelona
Julius-Maximilians-University of Wuerzburg - Wrzburg
British Columbia Cancer Agency Branch - Vancover
Oslo University Hospital HE - Oslo
Fundacio Clinic - Barcelona

International Classification:

C40B 30/04

US Classification:

506 9

Abstract:

Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

US Patent:

20200143906, May 7, 2020

Filed:

Jan 17, 2020

Appl. No.:

16/746347

Inventors:

- Bethesda MD, US
- Vancouver, CA
- Tucson AZ, US
- Barcelona, ES
- Cleveland OH, US
- Lincoln NE, US
- Portland OR, US
- Würzburg, DE
- Oslo, NO
Kai Fu - Omaha NE, US
Paul Michael Williams - Great Falls VA, US
Chih-Jian Lih - Gaithersburg MD, US
Elaine S. Jaffe - Great Falls VA, US
Rita M. Braziel - West Linn OR, US
Andreas Rosenwald - Würzburg, DE
Erlend B. Smeland - Oslo, NO
Wing C. Chan - Pasadena CA, US
German Ott - Bietigheim-Bissingen, DE
Jan Delabie - Toronto, CA
Dennis Weisenburger - Glendora CA, US

Assignee:

The United States of America,as represented by the Secretary,Department of Health and Human Services - Bethesda MD
British Columbia Cancer Agency Branch - Vancouver
Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ
Universitat de Barcelona - Barcelona
Hospital Clinic de Barcelona - Barcelona
The Cleveland Clinic Foundation - Cleveland OH
Board of Regents of the University of Nebraska - Lincoln NE
Oregon Health & Science University - Portland OR
Julius-Maximilians-University of Würzburg - Würzburg
Oslo University Hospital HF - Oslo

International Classification:

G16B 25/00
C12Q 1/6886
G16B 5/00

Abstract:

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

US Patent:

20200105364, Apr 2, 2020

Filed:

Dec 13, 2019

Appl. No.:

16/713528

Inventors:

- Bethesda MD, US
- Vancouver, CA
- Rochester MN, US
- Wurzburg, DE
- Lincoln NE, US
- Oslo, NO
- Barcelona, ES
- Stuttgart, DE
- Portland OR, US
- Duarte CA, US
- Cleveland OH, US
German Ott - Bitighein-Bissingen, DE
Rita Braziel - West Linn OR, US
Elaine S. Jaffe - Great Falls VA, US
Kai Fu - Omaha NE, US
Wing C. Chan - Pasadena CA, US
Joo Song - Duarte CA, US
James R. Cook - Shaker Heights OH, US

Assignee:

The United States of America,as represented by the Secretary,Department of Health and Human Services - Bethesda MD
British Columbia Cancer Agency Branch - Vancouver BC
Mayo Foundation for Medical Education and Research - Rochester MN
Julius-Maximilians-University of Würzburg - Würzburg MN
Board of Regents of the University of Nebraska - Lincoln NE
Oslo University Hospital HF - Oslo NE
Hospital Clinic de Barcelona - Barcelona NE
Universitat de Barcelona - Barcelona NE
Institut D? Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) - Barcelona NE
Robert Bosch Gesellschaft fuer medizinische Forschung mbH - Stuttgart NE
Oregon Health & Science University - Portland OR
City of Hope - Duarte CA
The Cleveland Clinic Foundation - Cleveland OH

International Classification:

G16B 5/00
C12Q 1/6886
G16B 25/10

Abstract:

In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

US Patent:

20160283653, Sep 29, 2016

Filed:

Nov 5, 2014

Appl. No.:

15/035101

Inventors:

- Bethesda MD, US
- Vancouver, CA
- Tucson AZ, US
- Barcelona, ES
- Cleveland OH, US
- Lincoln NE, US
- Portland OR, US
- Wuerzburg, DE
- Oslo, NO
Kai Fu - Omaha NE, US
Paul Michael Williams - Great Falls VA, US
Chih-Jian Lih - Gaithersburg MD, US
Elaine S. Jaffe - Great Falls VA, US
Rita M. Braziel - West Linn OR, US
Andreas Rosenwald - Wuerzburg, DE
Erlend B. Smeland - Oslo, NO
Wing C. Chan - Pasadena CA, US
German Ott - Bietigheim-Bissingen, DE
Jan Delabie - Toronto, CA
Dennis Weisenburger - Glendora CA, US

International Classification:

G06F 19/20
G06F 19/12
C12Q 1/68

Abstract:

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.